Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lexagene Holdings Inc V.LXG


Primary Symbol: LXXGQ

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Post by ARIMA11on Jan 27, 2022 11:51am
311 Views
Post# 34366880

Interesting

Interestinghttps://www.bloomberg.com/opinion/articles/2022-01-27/after-covid-antimicrobial-resistance-is-the-world-s-biggest-health-emergency?

Covid-19 has claimed nearly 6 million lives. Antimicrobial resistance may claim 10 million annually by 2050 — and that figure is starting to look low.

A new study published last week in the Lancet presents the first global estimates of the burden of antimicrobial resistance — and they confirm the worst fears. The authors estimate that in 2019, nearly 1.3 million deaths were directly attributed to infections that were drug-resistant and more than 4.9 million deaths were associated with drug resistance. One in five AMR deaths occurred in a child under the age of five.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext
 
<< Previous
Bullboard Posts
Next >>